Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10315008 | 1.00 | KIF11 (0.52) | KIF11SIRT2 | |
| SCHEMBL17258330 | 1.00 | KIF11 (0.52) | KIF11SIRT2 | |
| SCHEMBL10315743 | 0.88 | KIF11 (0.47) | KIF11SIRT2 | |
| SCHEMBL1526445 | 0.83 | KIF11 (0.57) | KIF11SIRT2 | |
| SCHEMBL18764637 | 0.80 | KIF11 (0.53) | KIF11 | |
| SCHEMBL18764634 | 0.80 | KIF11 (0.53) | KIF11 | |
| SCHEMBL18764574 | 0.79 | KIF11 (0.49) | KIF11 | |
| SCHEMBL18764694 | 0.79 | KIF11 (0.49) | KIF11 | |
| SCHEMBL18764571 | 0.79 | KIF11 (0.49) | KIF11 | |
| SCHEMBL18764587 | 0.79 | KIF11 (0.52) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | claimed |
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | claimed |
| WO-2017068596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-04-27 | — | — | WO | claimed |
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | UWM RESEARCH FOUNDATION, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | disclosed |
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | disclosed |
| US-20180258135-A1 | NOVEL HDAC INHIBITORS AND METHODS OF TREATMENT USING THE SAME | UWM RESEARCH FOUNDATION, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2017068596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017039726-A1 | NOVEL HDAC INHIBITORS AND METHODS OF TREATMENT USING THE SAME | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9469656-B2 | HDAC inhibitors as anti-cancer agents | THE UNIVERSITY OF TOLEDO (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150329560-A1 | HDAC Inhibitors as Anti-Cancer Agents | THE UNIVERSITY OF TOLEDO (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2015175770-A1 | HDAC INHIBITORS AS ANTI-CANCER AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | IL17A, HSD17B7, SULT1E1 | KIF11 1550/4885SIRT2 3962/4885 |
| US-20150329560-A1 | HDAC Inhibitors as Anti-Cancer Agents | HDAC1, HDAC4, HDAC5 | KIF11 1452/4885SIRT2 60/4885 |
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | HDAC4, HDAC2, HDAC8 | KIF11 1702/4885SIRT2 64/4885 |
| US-20180258135-A1 | NOVEL HDAC INHIBITORS AND METHODS OF TREATMENT USING THE SAME | HDAC4, HDAC1, HDAC2 | KIF11 1426/4885SIRT2 51/4885 |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | SULT1E1, IL17A, TET1 | KIF11 1467/4885SIRT2 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.